Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
| Indexado |
|
||||
| DOI | 10.1200/JCO.20.01605 | ||||
| Año | 2021 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Abstract
CONCLUSION At 5 years, nivolumab continued to demonstrate a survival benefit versus docetaxel, exhibiting a five-fold increase in OS rate, with no new safety signals. These data represent the first report of 5-year outcomes from randomized phase III trials of a programmed death-1 inhibitor in previously treated, advanced NSCLC. (C) 2021 by American Society of Clinical Oncology
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Borghaei, Hossein | Hombre |
Fox Chase Canc Ctr - Estados Unidos
Fox Chase Cancer Center - Estados Unidos |
| 2 | Gettinger, S. | Hombre |
Yale Comprehens Canc Ctr - Estados Unidos
Yale Cancer Center - Estados Unidos |
| 3 | Vokes, Everett E. | Hombre |
UNIV CHICAGO - Estados Unidos
The University of Chicago Medicine - Estados Unidos |
| 4 | Chow, Laura Q. M. | Mujer |
UNIV WASHINGTON - Estados Unidos
University of Washington - Estados Unidos |
| 5 | Burgio, M. A. | Hombre |
Ist Sci Romagnolo Studio & Cura Tumori Irst Irccs - Italia
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - Italia |
| 6 | de Castro Carpeno, Javier | Hombre |
Hospital de Madrid - España
Hosp Madrid - España |
| 6 | Carpeno, Javier De Castro | Hombre |
Hosp Madrid - España
Hospital de Madrid - España |
| 7 | Pluzanski, Adam | Hombre |
Maria Sklodowska Curie Inst Oncol - Polonia
Maria Sklodowska-Curie National Research Institute of Oncology Warsaw - Polonia Maria Sklodowska-Curie National Research Institute of Oncology - Polonia |
| 8 | Arrieta, Oscar | Hombre |
INST NACL CANCEROL - México
|
| 8 | Arrietac, Oscar | Hombre |
Instituto Nacional de Cancerologia, México - México
INST NACL CANCEROL - México |
| 9 | AREN-FRONTERA, OSVALDO RUDY | Hombre |
Ctr Invest Clin Bradford Hill - Chile
Ctr Int Estudios Clin - Chile Centro Internacional de Estudios Clinicos - Chile |
| 10 | Chiari, Rita | Mujer |
Osped S Maria Misericordia - Italia
Azienda Ospedaliera di Perugia - Italia |
| 11 | Butts, C. | Hombre |
Cross Canc Inst - Canadá
Cross Cancer Institute - Canadá |
| 12 | Wojcik-Tomaszewska, Joanna | Mujer |
Prov Ctr Oncol Gdansk - Polonia
Provincial Center of Oncology in Gdańsk - Polonia |
| 13 | Coudert, B. | Hombre |
Ctr Georges Francois Leclerc - Francia
Centre Georges-François Leclerc - Francia |
| 14 | Garassino, Marina Chiara | Mujer |
Inst Nazl Studio & La Cura - Italia
Instituto Nazionale per la Cura e to Studio dei Tumori - Italia Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - Italia |
| 15 | Ready, Neal E. | Hombre |
Duke Univ - Estados Unidos
Duke University Medical Center - Estados Unidos |
| 16 | Felip, E. | Mujer |
Vall dHebron Univ Hosp - España
Vall dHebron Inst Oncol - España Vall d‘Hebron Institut de Oncologia - España |
| 17 | Alonso Garcia, M. | Mujer |
Hosp Univ Virgen Del Rocio - España
Hospital Universitario Virgen del Rocío - España |
| 18 | Waterhouse, D. | Hombre |
Oncol Hematol Care Inc - Estados Unidos
Oncology Hematology Care, Inc. - Estados Unidos |
| 19 | Domine, M. | Hombre |
FDN JIMENEZ DIAZ - España
Hospital Universitario Fundación Jiménez Díaz - España Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz - España |
| 20 | Barlesi, F. | Hombre |
Aix Marseille Univ - Francia
Centre de Recherche en Cancerologie de Marseille - Francia |
| 21 | Antonia, S. J. | Hombre |
H Lee Moffitt Canc Ctr & Res Inst - Estados Unidos
Moffitt Cancer Center - Estados Unidos |
| 22 | Wohlleber, M. | Hombre |
Robert Bosch Canc Ctr - Alemania
Robert Bosch GmbH - Alemania |
| 23 | Gerber, David E. | Hombre |
UT Southwestern Med Ctr - Estados Unidos
UT Southwestern Medical Center - Estados Unidos |
| 24 | Czyzewicz, Grzegorz | Hombre |
John Paul 2 Hosp - Polonia
John Paul II Hospital, Krakow - Polonia |
| 25 | Spigel, David R. | Hombre |
Sarah Cannon Res Inst Tennessee Oncol PLLC - Estados Unidos
Sarah Cannon Research Institute - Estados Unidos |
| 26 | Crino, L. | Hombre |
Ist Sci Romagnolo Studio & Cura Tumori Irst Irccs - Italia
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - Italia |
| 27 | Eberhardt, Wilfried Enst Erich | Hombre |
Univ Med Essen - Alemania
Ruhrlandklin - Alemania Ruhrlandklinik - Alemania |
| 28 | Li, Xiang-Dong | - |
Bristol Myers Squibb - Estados Unidos
Bristol-Myers Squibb - Estados Unidos |
| 29 | Marimuthu, S. | - |
Bristol Myers Squibb - Estados Unidos
Bristol-Myers Squibb - Estados Unidos |
| 30 | Brahmer, Julie R. | Mujer |
Johns Hopkins Kimmel Canc Ctr - Estados Unidos
|
| 30 | Brahmerc, Julie | Mujer |
The Sidney Kimmel Comprehensive Cancer Center - Estados Unidos
Johns Hopkins Kimmel Canc Ctr - Estados Unidos |
| Fuente |
|---|
| Bristol-Myers Squibb |
| National Center for Advancing Translational Sciences |
| Bristol Myers Squibb |
| ONO Pharmaceutical Company Ltd. |
| Ono Pharmaceutical Company |
| Agradecimiento |
|---|
| We thank the patients and their families, as well as the participating trial teams, for making this trial possible; Jamie Yingst of Bristol Myers Squibb for contributing as protocol manager of this trial; and the staff of Dako, an Agilent Technologies, Inc, company, for collaborative development of the PD-L1 IHC 28-8 pharmDx assay. This study was sponsored by Bristol Myers Squibb and Ono Pharmaceutical Company Ltd. Medical writing and editorial assistance were provided by Amy Horne, MSc, of Caudex and was funded by Bristol Myers Squibb. |
| We thank the patients and their families, as well as the participating trial teams, for making this trial possible; Jamie Yingst of Bristol Myers Squibb for contributing as protocol manager of this trial; and the staff of Dako, an Agilent Technologies, Inc, company, for collaborative development of the PD-L1 IHC 28-8 pharmDx assay. This study was sponsored by Bristol Myers Squibb and Ono Pharmaceutical Company Ltd. Medical writing and editorial assistance were provided by Amy Horne, MSc, of Caudex and was funded by Bristol Myers Squibb. |
